# Copper-Targeted Therapy in Experimental Endometriosis: Effects of Ammonium Tetrathiomolybdate on Markers of the Interconnected Processes of Inflammation, Innervation, and Fibrogenesis

**Authors:** María Belén Delsouc, Rocío Ayelem Conforti, Ana Sofia Zabala, Verónica Palmira Filippa, Leonardo Mariño-Repizo, Sandra Silvina Vallcaneras, Marilina Casais

PMC · DOI: 10.3390/ijms27021099 · International Journal of Molecular Sciences · 2026-01-22

## TL;DR

This study explores a new treatment for endometriosis using a copper-chelating drug that reduces inflammation, nerve growth, and fibrosis in mice.

## Contribution

The study introduces copper-targeted therapy with ammonium tetrathiomolybdate as a novel approach to modulate multiple interconnected endometriosis pathways.

## Key findings

- Ammonium tetrathiomolybdate significantly reduced inflammatory and fibrogenic markers in endometriotic lesions.
- The drug lowered neurotrophin and nociceptive markers, suggesting a reduction in pain-related mechanisms.
- Collagen content in lesions was decreased, indicating reduced fibrosis.

## Abstract

Endometriosis (EDT) is a chronic, estrogen-dependent disease characterized by inflammation, fibrosis, pelvic pain, and infertility. Current therapies show limited long-term efficacy and adverse effects, underscoring the need for novel therapeutic approaches. Elevated copper (Cu) levels have been reported in both patients and animal models of EDT, making Cu chelation a promising strategy. This work aimed to evaluate the impact of ammonium tetrathiomolybdate (TM) on the expression of markers related to the interconnected processes of inflammation, innervation, and fibrogenesis in mice with induced EDT. Twenty-four female C57BL/6 mice were assigned to Sham, EDT, or EDT+TM groups. Treatment with TM began on postoperative day 15, with samples collected one month after EDT induction. Peritoneal fluid cytokines (TNF-α, IL-1β, IL-6, TGF-β1) were quantified by ELISA. Endometriotic-like lesions were examined for mRNA expression of cytokines, neurotrophins (Ngf, Bdnf, Ngfr), neural markers (Uchl1, Gap43), neuropeptides and nociceptive markers (Tac1/Tacr1, Calca/Calcrl/Ramp1, Trpv1), and fibrogenic markers (Vim, Acta2, Col1a1, Fmod) by RT-qPCR. Neurotrophin protein levels were measured by ELISA, and collagen content was assessed through Masson’s staining. TM significantly modulated inflammatory, neural, nociceptive, and fibrogenic markers, reducing most of them along with collagen content. These findings suggest that TM could impact key pathological mechanisms involved in EDT.

## Linked entities

- **Genes:** NGF (nerve growth factor) [NCBI Gene 4803], BDNF (brain derived neurotrophic factor) [NCBI Gene 627], NGFR (nerve growth factor receptor) [NCBI Gene 4804], UCHL1 (ubiquitin C-terminal hydrolase L1) [NCBI Gene 7345], GAP43 (growth associated protein 43) [NCBI Gene 2596], TAC1 (tachykinin precursor 1) [NCBI Gene 6863], TACR1 (tachykinin receptor 1) [NCBI Gene 6869], CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796], CALCRL (calcitonin receptor like receptor) [NCBI Gene 10203], RAMP1 (receptor activity modifying protein 1) [NCBI Gene 10267], TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442], VIM (vimentin) [NCBI Gene 7431], ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], FMOD (fibromodulin) [NCBI Gene 2331]
- **Proteins:** TNF (tumor necrosis factor), IL1B (interleukin 1 beta), IL6 (interleukin 6), TGFB1 (transforming growth factor beta 1)
- **Chemicals:** ammonium tetrathiomolybdate (PubChem CID 15251598)
- **Diseases:** endometriosis (MONDO:0005133)

## Full-text entities

- **Genes:** Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Gap43 (growth associated protein 43) [NCBI Gene 14432] {aka B-50, Basp2, GAP-43}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Vim (vimentin) [NCBI Gene 22352], Ramp1 (receptor (calcitonin) activity modifying protein 1) [NCBI Gene 51801] {aka 9130218E19Rik}, Uchl1 (ubiquitin carboxy-terminal hydrolase L1) [NCBI Gene 22223] {aka PGP 9.5, PGP9.5, UCH-L1, UCHL-1, gad}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Fmod (fibromodulin) [NCBI Gene 14264] {aka FM, SLRR2E}, Calca (calcitonin/calcitonin-related polypeptide, alpha) [NCBI Gene 12310] {aka CA, CGRP-1, CGRP1, Calc, Calc1, Cgrp}, Tac1 (tachykinin 1) [NCBI Gene 21333] {aka 4930528L02Rik, NK-1, NK1, Nkna, PPT-A, PPTA}, Ngf (nerve growth factor) [NCBI Gene 18049] {aka Ngfb, beta-NGF}, Col1a1 (collagen, type I, alpha 1) [NCBI Gene 12842] {aka Col1a-1, Cola-1, Cola1, Mov-13, Mov13}, Calcrl (calcitonin receptor-like) [NCBI Gene 54598] {aka CRLR}, Ngfr (nerve growth factor receptor (TNFR superfamily, member 16)) [NCBI Gene 18053] {aka LNGFR, Tnfrsf16, p75, p75NGFR, p75NTR}, Acta2 (actin alpha 2, smooth muscle, aorta) [NCBI Gene 11475] {aka 0610041G09Rik, Actvs, SMAalpha, SMalphaA, a-SMA, alphaSMA}, Bdnf (brain derived neurotrophic factor) [NCBI Gene 12064], Tacr1 (tachykinin receptor 1) [NCBI Gene 21336] {aka Nk1r, Spr, Tac1r}, Trpv1 (transient receptor potential cation channel, subfamily V, member 1) [NCBI Gene 193034] {aka OTRPC1, TRPV1alpha, TRPV1beta, VR-1, Vr1}
- **Diseases:** Inflammation (MESH:D007249), infertility (MESH:D007246), fibrosis (MESH:D005355), pelvic pain (MESH:D017699), nociceptive (MESH:D059226), EDT (MESH:D004715)
- **Chemicals:** Copper (MESH:D003300), Ammonium Tetrathiomolybdate (MESH:C020809)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12842519/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12842519/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12842519/full.md

---
Source: https://tomesphere.com/paper/PMC12842519